Aptorum Group

Aptorum Group PEG

Delisted·Sep 22, 2026

The PEG Ratio (Price/Earnings-to-Growth) of Aptorum Group (APM) as of Oct 29, 2026 is -0.40.

PEG

-0.40

Last updated:

PEG Ratio (Price/Earnings-to-Growth) of Aptorum Group is 2025 -0.40 . PEG Ratio (Price/Earnings-to-Growth) of Aptorum Group was 2024 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Aptorum Group Stock analysis

What does Aptorum Group do? Aptorum Group Ltd. develops pharmaceutical products targeting unmet medical needs in infectious diseases, cancers, metabolic disorders, and neurology. The company leverages drug discovery platforms to screen approved drug molecules and microbiome-based research for metabolic treatments. It commercializes therapeutic assets through systematic screening and microbiome research, focusing on diseases like infectious conditions, cancer, and metabolic disorders. The company also pursues projects in gastroenterology, women’s health, and surgical robotics, alongside natural supplements for menopausal symptoms. Aptorum Group Ltd. generates revenue by advancing therapeutic and diagnostic projects across multiple disease areas. Its products include treatments for infectious diseases, cancers, and metabolic conditions, developed through drug discovery platforms and microbiome research. The company targets healthcare providers, pharmaceutical partners, and patients seeking innovative treatments for conditions with limited existing options. Segments include infectious disease therapies, cancer treatments, metabolic disorder solutions, and women’s health products. The company’s revenue streams come from the development and commercialization of therapeutic assets. It focuses on drug discovery through systematic screening of approved molecules and microbiome-based research for metabolic diseases. Projects in neurology, gastroenterology, and women’s health contribute to its product portfolio, alongside surgical robotics and natural supplements for menopausal symptoms. Aptorum Group Ltd. serves medical professionals and patients requiring novel treatments for underserved disease areas. Aptorum Group is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Aptorum Group stock

PEG Ratio (Price/Earnings-to-Growth) of Aptorum Group is -0.40 in 2025.

On Eulerpool you can find the complete historical development of PEG Ratio (Price/Earnings-to-Growth) Aptorum Group since 2006 – with annual values, charts, and detailed analysis.

The PEG ratio adjusts the P/E ratio by the expected earnings growth rate. A PEG below 1 may indicate an undervalued stock relative to its growth potential.

PEG = P/E Ratio / Expected Annual EPS Growth Rate

To evaluate PEG Ratio (Price/Earnings-to-Growth)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for PEG Ratio (Price/Earnings-to-Growth).

A 'good' varies by industry and company stage. On Eulerpool, you can compare PEG Ratio (Price/Earnings-to-Growth)'s Aptorum Group with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Aptorum Group

All Key Metrics — Aptorum Group